Test Price
1,100 AED✅ Home Collection Available
Imatinib Resistance Mutation Analysis (IRMA) in UAE | 1100 AED | 2026 DHA Guidelines
تحليل طفرات مقاومة إيماتينيب في الإمارات | 1100 درهم | معتمد من هيئة الصحة بدبي
Precision-guided sequencing to decode pharmacogenomic resistance in CML and Ph+ ALL, empowering oncologists with actionable mutational data for second- and third-line TKI selection.
Executive Summary & Critical Pre-Analytical Mandate
ملخص تنفيذي: يضمن هذا التحليل الجيني المتقدم تحديدًا دقيقًا لطفرات نطاق كيناز BCR-ABL1 المسببة لمقاومة إيماتينيب، باستخدام تقنية تسلسل الحمض النووي (Sanger Sequencing) وفقًا لأعلى معايير الجودة العالمية، مما يوفر توجيهًا علاجيًا حاسمًا لمرضى ابيضاض الدم النقوي المزمن وسرطان الدم الليمفاوي الحاد.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing & Sanger Sequencing.
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Logistics, ensuring sample integrity from your doorstep to our lab. VIP Mobile Phlebotomy available 8 AM - 11 PM.
- Clinical Guidance: Complimentary Telephonic Post-Test Clinical Guidance to contextualize mutational findings for your care team.
- Insurance & Verification: Direct Billing Support via WhatsApp at +971 54 548 8731.
Overview: Mutational Profiling for Targeted Oncology
The Imatinib Resistance Mutation Analysis (IRMA) is a specialized pharmacogenomic test that sequences the BCR-ABL kinase domain to detect point mutations conferring resistance to imatinib and other Tyrosine Kinase Inhibitors (TKIs). يكشف هذا الفحص الدقيق عن الطفرات الجينية المسؤولة عن فشل العلاج، موجهًا الأطباء نحو الجيل التالي من مثبطات التيروزين كيناز.
| Feature | Our Test (ISO-Certified IRMA) | Closest Alternative (Conventional Sequencing) |
|---|---|---|
| Methodological Precision | High-Fidelity Sanger Sequencing with >10% Variant Sensitivity for clinically relevant clones. | May lack the dedicated analytical sensitivity for low-level resistant clones. |
| Clinical Report Speed | 6-Day Dedicated TAT (Sample Mon by 11 am; Report Sat). | Variable, often >10 days due to non-prioritized batch processing. |
| Regulatory Compliance | Full DHA/MOHAP, UAE PDPL, and ISO 9001:2015 compliance. | Compliance status may be unverified or non-localized. |
Physician Insight & Safety Protocol
"As an oncologist, I view the IRMA test not just as a lab result, but as a critical compass guiding us away from ineffective therapies and towards durable molecular responses. The identification of specific kinase domain mutations, such as T315I, fundamentally dictates our next therapeutic move, and the clinical context of the patient's disease phase must always be correlated with these findings."
— Dr. Prabhakar Reddy, DHA License: 61713011
Critical Medication Warning
Do not discontinue or modify your prescribed TKI therapy based on these results without consulting your treating oncologist. A negative report for one mutation does not exclude other resistance mechanisms.
Safety Exclusion Criteria & ER Red Flags
- Exclusion: Inadequate or clotted samples, failure to provide the latest BCR-ABL Quantitative report, or samples not maintained at refrigerated temperature (DO NOT FREEZE).
- Immediate ER Visit Required: If the patient experiences sudden high fever, uncontrolled bleeding, severe bone pain, or neurological symptoms, these are oncological emergencies unrelated to the test scheduling and require immediate medical attention.
Patient FAQ & Clinical Guidance
1. What exactly does the IRMA test look for, and why is my BCR-ABL report needed?
The IRMA test performs direct DNA sequencing of the BCR-ABL kinase domain to pinpoint specific genetic mutations that cause your current therapy to fail, which is essential for your doctor to choose the next most effective targeted drug. يبحث التحليل عن طفرات جينية محددة تمنع دواء إيماتينيب من العمل، وتقرير BCR-ABL الكمي ضروري لتفسير النتائج بدقة ضمن سياق استجابتك الحالية للعلاج.
2. When is the right time for my oncologist to order this resistance mutation analysis?
Your oncologist will typically order this test upon confirmed loss of molecular response, a 5-10 fold rise in BCR-ABL transcripts, or progression to accelerated or blast phase disease, as per 2026 DHA guidelines. يطلب طبيب الأورام هذا الفحص عند فقدان الاستجابة الجزيئية أو ارتفاع ملحوظ في مستويات BCR-ABL، مما يشير لمقاومة الدواء، وهو إجراء أساسي لتغيير الخطة العلاجية فوراً.
3. How do I prepare for this, and what is the home collection process?
A simple, refrigerated 4 mL whole blood draw is all that is required, and we strictly adhere to a 'Do Not Freeze' cold-chain protocol from your arm to the analyzer to guarantee sample validity for testing. يتم سحب عينة دم بسيطة عبر خدمة التجميد المنزلي المتنقلة لدينا، مع الالتزام الصارم بنقلها مبردة وليس مجمدة، مما يحافظ على دقة التحليل الجيني الفائق.
Licensed Facility: 9834453 | ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139) | UAE Data Privacy Law (PDPL) Compliant
Federal Decree-Law No. 41 of 2024 (Art. 87) & CDS Law 2026 (Minors) Adhered To. All telephonic guidance is supportive and not a substitute for a physical consultation.
© 2026 Your Clinical Laboratory Partner in UAE. All rights reserved.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians